OKYO Pharma

OKYO

Market cap $82.4M

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain.

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases.

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO LONDON and NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company's global scientific network with premier European specialists.

LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.

OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scientific Advisory Board (SAB) meeting during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. The SAB meeting will bring together ophthalmology specialists and experts in corneal and ocular surface diseases to review clinical data for the company's lead investigational candidate, urcosimod.

LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting, scheduled to take place alongside the conference, will bring together prominent corneal and ocular surface disease specialists to review clinical data for the company's lead candidate, urcosimod and provide strategic guidance on the upcoming clinical program.

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion.

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares.